International Stem Cell Corp. (OTCMKTS:ISCO) Sees Significant Growth in Short Interest

International Stem Cell Corp. (OTCMKTS:ISCO) was the recipient of a large increase in short interest in the month of May. As of May 15th, there was short interest totaling 16,612 shares, an increase of 93.5% from the April 30th total of 8,585 shares. Based on an average trading volume of 4,812 shares, the short-interest ratio is currently 3.5 days. Currently, 0.7% of the shares of the company are sold short.

International Stem Cell Price Performance

OTCMKTS ISCO opened at $0.17 on Tuesday. The stock’s fifty day moving average price is $0.16 and its 200 day moving average price is $0.15. International Stem Cell has a 1 year low of $0.11 and a 1 year high of $0.27. The company has a market cap of $1.36 million, a price-to-earnings ratio of -2.83 and a beta of 0.07.

International Stem Cell (OTCMKTS:ISCO) last released its earnings results on Thursday, May 14th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter. The company had revenue of $2.32 million during the quarter.

About International Stem Cell

International Stem Cell Corporation (OTCMKTS:ISCO) is a biotechnology company focused on the development and commercialization of human parthenogenetic stem cells (hpSC) for therapeutic and research applications. Parthenogenetic stem cells are derived from unfertilized human eggs and offer a scalable, ethically noncontroversial source of pluripotent cells. ISCO’s proprietary hpSC lines can be directed to differentiate into a wide variety of cell types, enabling preclinical programs in areas such as neurodegenerative disease, liver disease, diabetes and corneal regeneration.

In addition to its therapeutic pipeline, International Stem Cell maintains a research products division that supplies hpSC lines, differentiated cell populations and media formulations to academic institutions, biotechnology companies and contract research organizations.